A Clinical Trial of Acyclovir for Viral Uveitis

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

NA

Total Enrollment

30 participants

Study Classification

INTERVENTIONAL

Study Start Date

2017-01-31

Study Completion Date

2021-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This project is designed to test the hypothesis that acyclovir is clinically useful for patients with refractory viral uveitis.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Cyclosporin Implant to Treat Uveitis

NCT00001737

Eye Disease Inflammation Uveitis

COMPLETED PHASE1

Cyclosporine 0.05% Eye Drops for Vernal Keratoconjunctivitis Trial

NCT05353101

Vernal Keratoconjunctivitis Cyclosporine 0.05% Eye Drops

COMPLETED PHASE1

Evaluate the Tolerance, Safety and Pharmacokinetics of Germinal Peptide Eye Drops in Healthy Volunteers

NCT03662971

Corneal Defect

COMPLETED PHASE1

Clinical Study for the Evaluation of Safety and Tolerability of SCAI-005 Eye Drops

NCT06969001

Wet Age Related Macular Degeneration

COMPLETED PHASE1

The Germinal Peptide Eye Drops in Healthy Volunteers in a Clinical Study

NCT03967548

Corneal Defect

COMPLETED PHASE1

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Approval of the study was obtained from the hospital's ethical committee. The study design and methodology followed the tenets of Declaration of Helsinki. All patients were provided with written informed consent and received a thorough explanation of the study design, aims, benefits and potential risks. This is a prospective non-comparative interventional study.

Aqueous humor samples were collected from participants to virus detection. Participants will take oral acyclovir 100 mg three times a day and data will be collected prospectively with regard to ophthalmologic outcomes. Study participants will be followed for up to 12 months to determine efficacy, and an additional 30 days for safety reports. Descriptive statistics will be gathered on participant demographics, uveitis characteristics, change in immunosuppressive medications, number of responders, ophthalmologic measures and change in corticosteroid dose during the study period.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Uveitis

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Patients with Viral Uveitis

Oral acyclovir 100 mg three times a day (TID).

Group Type EXPERIMENTAL

Acyclovir

Intervention Type DRUG

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Acyclovir

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Age between 18 and above.
* Chronic, vision threatening viral uveitis.
* Patients can't tolerate hormone therapy bacause of drug side effects.
* Consent to undergo anterior chamber tap and give aqueous for the study.
* Able to undergo relevant tests.
* Able to come for subsequent follow-up visits.
* Ability to provide informed consent.

Exclusion Criteria

* Patients who are allergic to ayclovir.
* Immunocompromised patients
* Positive for HIV, Hep B and Hep C
* Not keen on participating in the study
* Patients who are incapable, either by law or mental state, of giving consents in their own right.
* Patients who are either unable or unwilling to keep scheduled appointments and adhere to the other aspects of the protocol.
* Patients who are pregnant or breastfeeding.
* Any other specified reason as determined by the clinical investigator.

Minimum Eligible Age

18 Years

Maximum Eligible Age

80 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No